• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期前列腺癌患者骨转移治疗的当前概念与趋势

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer.

作者信息

Hegemann Miriam, Maas Moritz, Rausch Steffen, Walz Simon, Bedke Jens, Stenzl Arnulf, Todenhöfer Tilman

机构信息

Department of Urology, University Hospital Tuebingen, Tuebingen 72076, Germany.

出版信息

Asian J Androl. 2017 Dec 29;21(1):12-8. doi: 10.4103/aja.aja_59_17.

DOI:10.4103/aja.aja_59_17
PMID:29286005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6337943/
Abstract

Bone metastases have a major impact on quality of life and survival of patients with advanced prostate cancer. In the last decade, the development and approval of substances inhibiting the vicious cycle of bone metastases have enabled the reduction of complications caused by bone metastases in patients with castration-resistant prostate cancer. These drugs have raised awareness of the importance of skeletal-related events which in the meantime represent an important end point also in trials using agents not specifically designed for bone lesions. Second-generation antihormonal drugs such as enzalutamide or abiraterone have been shown to have a positive impact on the incidence of skeletal complications and therefore provide an important tool in the armamentarium used for treating bone metastases. Radiopharmaceuticals such as radium-223 dichloride ([223Ra]) have been demonstrated not only to reduce skeletal-related events and bone-related pain, but also to prolong overall survival, thereby being the first bone-targeting agent showing a survival benefit. As previous studies have not provided an obvious benefit of bone-targeted lesions in castration-sensitive disease, the use of these agents is not recommended. In oligometastatic prostate cancer, the role of local treatment of metastases using stereotactic radiation or radiosurgery is a matter of intense debates and may play an increasing role in the future.

摘要

骨转移对晚期前列腺癌患者的生活质量和生存有着重大影响。在过去十年中,抑制骨转移恶性循环的药物的研发和获批,使得去势抵抗性前列腺癌患者因骨转移引起的并发症有所减少。这些药物提高了人们对骨相关事件重要性的认识,与此同时,骨相关事件在使用并非专门针对骨病变设计的药物的试验中也成为一个重要的终点。第二代抗激素药物,如恩杂鲁胺或阿比特龙,已被证明对骨骼并发症的发生率有积极影响,因此为治疗骨转移的药物库提供了一种重要工具。二氯化镭([223Ra])等放射性药物不仅能减少骨相关事件和骨相关疼痛,还能延长总生存期,从而成为首个显示出生存获益的骨靶向药物。由于先前的研究未在去势敏感性疾病中显示出骨靶向病变的明显益处,因此不建议使用这些药物。在寡转移性前列腺癌中,使用立体定向放射或放射外科对转移灶进行局部治疗的作用存在激烈争论,且可能在未来发挥越来越大的作用。

相似文献

1
Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer.晚期前列腺癌患者骨转移治疗的当前概念与趋势
Asian J Androl. 2017 Dec 29;21(1):12-8. doi: 10.4103/aja.aja_59_17.
2
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.骨骼转移及抗雄激素药物和骨靶向药物对去势抵抗性前列腺癌患者的影响。
Cancer Treat Rev. 2016 Mar;44:61-73. doi: 10.1016/j.ctrv.2016.02.002. Epub 2016 Feb 12.
3
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.镭-223在转移性去势抵抗性前列腺癌不断增加的治疗手段中的新作用。
Expert Opin Pharmacother. 2017 Jun;18(9):899-908. doi: 10.1080/14656566.2017.1323875. Epub 2017 May 8.
4
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.镭-223 单独或联合醋酸阿比特龙/泼尼松或恩扎鲁胺治疗转移性去势抵抗性前列腺癌(mCRPC)患者的定量骨扫描反应的随机 IIa 期研究。
ESMO Open. 2021 Apr;6(2):100082. doi: 10.1016/j.esmoop.2021.100082. Epub 2021 Mar 19.
5
Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review.前列腺癌患者的骨骼健康问题:一项基于证据的综述。
World J Mens Health. 2020 Apr;38(2):151-163. doi: 10.5534/wjmh.190044. Epub 2019 May 2.
6
Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide.寡进展性转移性去势抵抗性前列腺癌在阿比特龙或恩杂鲁胺治疗期间行立体定向体部放疗。
Tumori. 2023 Aug;109(4):413-417. doi: 10.1177/03008916221132592. Epub 2022 Nov 10.
7
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.镭-223 二氯化物对去势抵抗性前列腺癌伴骨转移患者症状性骨骼事件的影响:来自一项 3 期、双盲、随机试验的结果。
Lancet Oncol. 2014 Jun;15(7):738-46. doi: 10.1016/S1470-2045(14)70183-4. Epub 2014 May 13.
8
A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).一项转移性去势抵抗性前列腺癌寡转移患者中应用发射阿尔法粒子的镭-223进行转移灶定向治疗的 II 期随机试验(MEDAL)。
BMC Urol. 2023 Mar 6;23(1):33. doi: 10.1186/s12894-023-01202-z.
9
Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.骨转移去势抵抗性前列腺癌患者的治疗机会
Crit Rev Oncol Hematol. 2014 Aug;91(2):197-209. doi: 10.1016/j.critrevonc.2014.01.003. Epub 2014 Jan 17.
10
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.

引用本文的文献

1
Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications.前列腺癌中的骨转移与健康:从病理生理学到临床意义
Cancers (Basel). 2023 Feb 28;15(5):1518. doi: 10.3390/cancers15051518.
2
Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events.实体瘤骨转移且无骨靶向药物治疗史患者的医疗资源利用情况及相关费用:有和无骨骼相关事件患者的对比分析。
Eur J Health Econ. 2021 Mar;22(2):243-254. doi: 10.1007/s10198-020-01247-z. Epub 2021 Jan 18.
3
The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb.亲脂性双膦酸盐 BPH1222 在黑色素瘤模型中的抗肿瘤作用:PI3K/Akt 通路和小 G 蛋白 Rheb 的作用。
Int J Mol Sci. 2019 Oct 3;20(19):4917. doi: 10.3390/ijms20194917.
4
Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review.前列腺癌患者的骨骼健康问题:一项基于证据的综述。
World J Mens Health. 2020 Apr;38(2):151-163. doi: 10.5534/wjmh.190044. Epub 2019 May 2.
5
Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management.细胞外囊泡在前列腺癌发生、诊断及治疗中的作用
Front Oncol. 2018 Jun 13;8:222. doi: 10.3389/fonc.2018.00222. eCollection 2018.

本文引用的文献

1
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.EAU-ESTRO-SIOG 前列腺癌诊治指南。第二部分:复发、转移和去势抵抗性前列腺癌的治疗。
Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.
2
Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.在挽救性淋巴结清扫术前,使用(68)Ga-PSMA-HBED-CC检测复发性前列腺癌病灶比使用(18)F-氟乙基胆碱PET/CT更准确。
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1410-7. doi: 10.1007/s00259-016-3366-9. Epub 2016 Mar 19.
3
A review of recently published radiotherapy treatment guidelines for bone metastases: Contrasts or convergence?近期发布的骨转移瘤放射治疗指南综述:对比还是趋同?
J Bone Oncol. 2012 May 9;1(1):18-23. doi: 10.1016/j.jbo.2012.04.002. eCollection 2012 Jun.
4
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.去势抵抗性前列腺癌的试验设计与目标:前列腺癌临床试验工作组3的更新建议
J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22.
5
Cost of skeletal complications from bone metastases in six European countries.六个欧洲国家骨转移引起的骨骼并发症的成本。
J Med Econ. 2016 Jun;19(6):611-8. doi: 10.3111/13696998.2016.1150852. Epub 2016 Feb 23.
6
CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.CyberKnife 立体定向放射外科和立体定向消融放疗治疗前列腺癌骨转移患者。
Neoplasma. 2016;63(2):304-12. doi: 10.4149/218_150807N435.
7
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.多西他赛、唑来膦酸或两者联合添加至前列腺癌一线长期激素治疗(STAMPEDE):一项适应性、多组、多阶段、平台随机对照试验的生存结果
Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.
8
Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy.骨相关事件对接受雄激素剥夺治疗的转移性前列腺癌患者生存的影响。
Hong Kong Med J. 2016 Apr;22(2):106-15. doi: 10.12809/hkmj144449. Epub 2015 Dec 4.
9
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
10
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.寡转移去势抵抗性前列腺癌立体定向体部放疗后无进展生存的多中心分析。
Eur Urol. 2016 Jan;69(1):9-12. doi: 10.1016/j.eururo.2015.07.004. Epub 2015 Jul 16.